ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biologic response modifiers"

  • Abstract Number: 636 • 2017 ACR/ARHP Annual Meeting

    Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials

    Rochelle Castillo1, Khushboo Sheth2 and Santhanam Lakshminarayanan3, 1University of Connecticut, Farmington, CT, 2Rheumatology, Stanford University, Palo Alto, CA, 3Division of Rheumatology, University of Connecticut Health Center, Farmington, CT

    Background/Purpose: Co-medication of MTX with TNF inhibitors (TNFi) has proven superior to TNFi monotherapy in improving clinical outcomes in patients with RA. Whether this holds…
  • Abstract Number: 2906 • 2017 ACR/ARHP Annual Meeting

    Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries

    Dominick Sudano1, C. Kent Kwoh2, Lili Zhou3, Erin L. Ashbeck4 and Wei-Hsuan Lo-Ciganic5, 1University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, 2University of Arizona, Tucson, AZ, 3Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, 4The University of Arizona Arthritis Center, Tucson, AZ, 5Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Associate professor, TUCSON, AZ

    Background/Purpose: Coccidioidomycosis (Cocci) is a fungal infection endemic to seven states in the US. Biologic response modifiers (BRMs) have been shown to increase the risk…
  • Abstract Number: 2482 • 2016 ACR/ARHP Annual Meeting

    Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate

    I.M Visman1, MJ l'Ami2, Gertjan Wolbink3 and Mike T. Nurmohamed4,5, 1Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, 3Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, 4Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, 5Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands

    Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are effective, safe and widely used treatment for rheumatoid arthritis (RA). The therapy is often started in combination…
  • Abstract Number: 2641 • 2016 ACR/ARHP Annual Meeting

    Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA

    Sofia Ramiro1, Alexandre Sepriano1, Katerina Chatzidionysiou2, Jackie L. Nam3, Josef Smolen4, Désirée van der Heijde5, Maxime Dougados6, Ronald van Vollenhoven7, Johannes WJ Bijlsma8, GR Burmester9, Marieke Scholte-Voshaar10 and RBM Landewé11, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, 5Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Paris Descartes University, Paris, France, 7Amsterdam Rheumatology Center, Amsterdam, Netherlands, 8Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 9Charité – University Medicine Berlin, Berlin, Germany, 10EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, 11Amsterdam Medical Center, Amsterdam, Netherlands

    Background/Purpose: As part of the update of the EULAR recommendations for the management of RA, we performed a systematic literature review to assess the safety…
  • Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting

    Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study

    Carmen Bejerano1, Natividad Oreiro1, Carlos Fernandez-Lopez2, Jose A Pinto-Tasende1, Antonio Atanes1, Bruno De Aspe1, Genaro Graña Gil1, Mercedes Freire1, Manuel Acasuso3, Sonia Pertega4, Francisco J. de Toro1 and Francisco J Blanco1, 1Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, 2Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, 3Centro de Salud San Jose, XAP Coruna, A Coruna, Spain, 4Epidemiology Unit, INIBIC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

    Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…
  • Abstract Number: 1350 • 2016 ACR/ARHP Annual Meeting

    Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience

    Usman Ajaz1, Jeffrey R. Lisse2, Neil M. Ampel3 and Dominick Sudano4, 1Department of Medicine, University of Arizona, Tucson, AZ, 2Arizona Arthritis Center, University of Arizona, Tucson, AZ, 3Department of Infectious Disease, Southern AZ VA Medical Center, Tucson, AZ, 4Department of Rheumatology, University of Arizona, Tucson, AZ

    Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection that typically causes a self-limited pulmonary illness in the Southwestern United States,. Immunosuppressed patients are at…
  • Abstract Number: 548 • 2015 ACR/ARHP Annual Meeting

    Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab

    J Carter Thorne1, Gilles Boire2, Andrew Chow3, Kirsten Garces4, Fang Liu5, Melanie Poulin-Costello6, Valery Walker5 and Boulos Haraoui7, 1Southlake Regional Health Centre, Newmarket, ON, Canada, 2Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 3Credit Valley Rheumatology, Mississauga, ON, Canada, 4Amgen Canada Inc, Mississauga, ON, Canada, 5Optum, Burlington, ON, Canada, 6Amgen Canada Inc., Mississauga, ON, Canada, 7Institut de rhumatologie de Montréal, Montreal, QC, Canada

    Background/Purpose: The individual response to anti-TNFs etanercept (ETA), infliximab (INF) and adalimumab (ADA) in rheumatoid arthritis (RA) may vary. Options for managing inadequate response include…
  • Abstract Number: 601 • 2015 ACR/ARHP Annual Meeting

    Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis

    Antoine Vanier1, Florence Tubach2, Toni Alfaiate3, Xavier Mariette4 and Bruno Fautrel5, 1Biostatistics, Public Health and Medical Informatics, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6, Paris, France, 2Epidemiology and Clinical Research, AP-HP Bichat Hospital / University of Paris-Diderot / INSERM CIC-EC 1425, Paris, France, 3Epidemiology and Clinical Research, AP-HP Bichat Hospital / INSERM CIC-EC 1425, Paris, France, 4Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 5Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France

    Background/Purpose: Once remission is achieved for patients with rheumatoid arthritis (RA), treatment down-titration should be attempted, for safety issues or economic reasons. One of the…
  • Abstract Number: 2205 • 2014 ACR/ARHP Annual Meeting

    Management of Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease

    Dominick Sudano1, Varun Bhalla2, Neil M. Ampel3,4 and Jeffrey R. Lisse5, 1Rheumatology, University of Arizona, Tucson, AZ, 2University of Arizona, Tucson, AZ, 3Infectious Disease, University of Arizona, Tucson, AZ, 4Infectious Disease, Southern Arizona Veteran's Affairs Medical Center, Tucson, AZ, 5Department of Rheumatology, University of Arizona, Tucson, AZ

    Background/Purpose: In the Southwestern United States, coccidioidomycosis (valley fever) is an endemic fungal infection which typically causes a self-limited pulmonary illness. Immunosuppressed patients, including those…
  • Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting

    Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient

    Chisa Okura1, Yukio Yonemoto2, Koichi Okamura1, Tetsuya Kaneko3, Tsutomu Kobayashi1 and Kenji Takagishi1, 1Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, 3Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan

    Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…
  • Abstract Number: 382 • 2013 ACR/ARHP Annual Meeting

    Effect Of Biologic Disease Modifiers On Cardiovascular Risk Of Patients With Rheumatoid Arthritis – 2 Years Prospective Cohort Study

    Majed M. Khraishi1 and Rana Aslanov2, 1Nexus Clinical Research, St John's, NF, Canada, 2Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada

    Background/Purpose: People with RA have a higher risk for developing cardiovascular diseases than the general population. The pathogenic mechanisms in RA appear to be complex…
  • Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting

    The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort

    Stéphanie Emilie1, Cécile Gaujoux-Viala2, Benjamin Granger3, Anne-Christine Rat4, Bernard Combe5 and Bruno Fautrel6, 1Paris 6,Pierre and Marie Curie University, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, France, 2Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, 3Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, 4CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 5Rheumatology, Hopital Lapeyronie, Montpellier, France, 6Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France

    Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…
  • Abstract Number: 782 • 2012 ACR/ARHP Annual Meeting

    Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis

    Nigil Haroon1, Robert D. Inman2, Thomas J. Learch3, Michael H. Weisman4, Michael M. Ward5, John D. Reveille6 and Lianne S. Gensler7, 1Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, 2Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3Cedars-Sinai, Los Angeles, CA, 4Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 5Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, 6Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, 7Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: The influence of anti-TNF therapy on radiographic progression in ankylosing spondylitis (AS) is not well established. We studied this effect on radiographic progression in…
  • Abstract Number: 1827 • 2012 ACR/ARHP Annual Meeting

    Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis

    Vibeke Strand1, Thomas V. Jones2, Wenzhi Li3, Andrew S. Koenig4 and Sameer Kotak5, 1Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, 2Inflammation Specialty Care, Pfizer, Inc, Collegeville, PA, 3Pfizer Inc., Collegeville, PA, 4Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, 5Specialty Care, Pfizer Inc., New York, NY

    Background/Purpose: Active joint inflammation and structural damage in patients with rheumatoid arthritis (RA) often result in impaired physical function and ultimately work disability.1,2 Lost productivity…
  • Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting

    Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis

    Yukiko Kimura1, Jennifer E. Weiss2, Kathryn L. Haroldson1, Tzielan C. Lee3, Marilynn G. Punaro4, Sheila K. Feitosa de Oliveira5, C. Egla Rabinovich6, Meredith P. Riebschleger7, Jordi Anton8, Peter R. Blier9, Valeria Gerloni10, Melissa M. Hazen11, Elizabeth Kessler12, Karen Onel13, Murray H. Passo14, Robert M. Rennebohm15, Carol A. Wallace16, Patricia Woo17, Nico M. Wulffraat18 and CARRAnet Investigators19, 1Pediatric Rheumatology, JM Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, 2Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 3Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, 4Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 5Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 6Pediatric Rheumatology, Duke University Medical Center, Durham, NC, 7Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, 8Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, 9Pediatrics, Baystate Children's Hospital, Springfield, MA, 10Pediatric Rheumatology, Gaetano Pini Chair of Rheum, Milan, Italy, 11Division of Immunology, Boston Children's Hospital, Boston, MA, 12Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 13Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 14Pediatrics, Medical University of South Carolina, Charleston, SC, 15Pediatric Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, 16Pediatrics, Seattle Childrens Hospital, Seattle, WA, 17Division of Infection and Immunity, University College London, London, United Kingdom, 18Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 19Durham

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective.  Pulmonary artery…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology